---
ticker: "BRK-B"
company_name: "Berkshire Hathaway Inc."
sector: "equity"
asset_class: "equity"
analysis_date: "2026-03-24"
analyst: "opus-4.6 / inv-AI"
rating: "FAIRLY_PRICED"
rating_display: "Fairly Priced"
conviction_level: 8
confidence_score: 6.5
confidence_level: "MEDIUM-HIGH"
current_price: 479.33
fair_value:
  low: 406
  mid: 467
  high: 528
upside_to_mid: -2.6
cross_model_review:
  status: "PENDING"
  iterations: 0
  reviewer: "GPT-5.4"
  review_date: "2026-03-24"
report_html: "/reports/BRK-B.html"
---

# BRK-B — Berkshire Hathaway Inc.

Valuation Analysis | March 24, 2026 | Sector: Financials-Conglomerate | Version: v2.0

## IC Summary: BRK at 1.44x Book Is Fairly Priced — Iran War Creates Asymmetric Cash Deployment Opportunity, Buyback Resumption Signals Abel Confidence

At $479, Berkshire trades at 1.44x year-end 2025 book value ($332.55/share) and ~22.0x FY2025 operating earnings ($44.49B)[1] — modestly above 10-year averages on P/E but in line on P/B. Three material developments since our January report: (1) the Iran war (started Feb 28) creates the exact market dislocation Berkshire's $363B cash pile (pro-forma) was built for — war risk insurance repricing is a direct tailwind to reinsurance margins, while energy holdings (OXY, CVX) benefit from elevated crude; (2) Abel resumed share buybacks on March 4 ($226M) and invested his entire $15.3M take-home pay in BRK stock[2] — the strongest insider conviction signal since Buffett's buyback authorization; (3) FY2025 operating earnings declined to $44.49B from $47.44B, driven by insurance normalization (GEICO CR 84.7% vs. 81.5% in 2024)[3]. Our updated SOTP produces $453/share; P/B at 1.35x gives $449; P/E at 22x normalized gives $469; DCF with war-era cash optionality gives $520. Weighted fair value: $467. At $479, fairly priced with improving near-term R/R (0.82:1) and strongly favorable long-term R/R (3.11:1).

---

| Metric | Value |
|--------|-------|
| Current Price | $479.33 |
| Fair Value (Weighted) | $467 |
| Band | $406 - $528 |
| Rating | FAIRLY PRICED |
| Upside to Mid | -2.6% |
| R/R (Near-Term) | 0.82:1 |
| R/R (Long-Term) | 3.11:1 |
| Confidence | MEDIUM-HIGH (6.5/10) |

---

## Table of Contents

1. Key Metrics & Financials
2. What Changed Since January
3. Investment Thesis (Iran War Update)
4. Sum-of-the-Parts Valuation
5. All Valuation Methods
6. Fair Value Synthesis
7. Scenario Analysis & Risk/Reward
8. The Iran War Factor
9. The Abel Era: 83 Days In
10. PacifiCorp Update
11. Contrarian Checklists
12. Sources & Disclosures

---

## 1. Key Metrics & Financials

| Metric | Value | Context |
|--------|-------|---------|
| Book Value Per Share (YE 2025) | $332.55 | Up from $326 at Q3; $712B shareholders' equity[1] |
| P/B Ratio (Current) | 1.44x | $479 / $332.55. 10-yr median ~1.4x[8] |
| Operating Earnings (FY 2025) | $44.49B | Down from $47.44B in FY 2024[1] |
| Operating Earnings (Q4 2025) | $10.2B | Down 29.8% YoY on insurance normalization[1] |
| Operating P/E (FY 2025) | ~22.0x | $1.03T market cap / $44.49B operating earnings |
| Cash & T-Bills (YE 2025) | $373.3B | Down from $381.6B Q3 record; pro-forma ~$363B post-OxyChem[1] |
| Insurance Float | ~$176B | Year-end 2025 per annual report[1]. Zero-cost capital. |
| Market Cap | ~$1.03T | At $479.33/share |
| Dividend | $0 | No dividend. Never paid one. |
| Buybacks | $226M | Resumed March 4, 2026 — first since May 2024[2] |
| Equity Portfolio (13F) | $274.2B | Per Q4 2025 13F. Apple trimmed to 22.6%. New NYT stake[4] |
| 52-Week Range | $378 - $502 | Within 5% of highs despite war |
| Analyst Consensus | $550 | MarketBeat avg. Morningstar ~$530. Range $479-$597[5] |

### Operating Earnings Segment Breakdown (FY 2025)

| Segment | FY 2025 | FY 2024 | YoY Change |
|---------|---------|---------|------------|
| Insurance Underwriting | $9.5B | $11.4B | -16.7% |
| Insurance Investment Income | $12.5B | $9.8B | +27.6% |
| BNSF Railway | $5.5B | $5.0B | +8.9% |
| BHE (Utilities/Energy) | $3.5B | $3.7B | -5.4% |
| Manufacturing/Service/Retail | $13.5B | $13.6B | -0.7% |
| Other | — | — | — |
| **Total Operating Earnings** | **$44.49B** | **$47.44B** | **-6.2%** |

Key highlights: GEICO combined ratio 84.7% (vs 81.5% in 2024) — still excellent but normalizing from historic lows. Insurance investment income surged on higher T-bill yields. BNSF recovery. BHE weighed down by PacifiCorp provisions.

---

## 2. What Changed Since January

### Bullish Developments

1. **Buyback Resumption (March 4):** Abel purchased $226M of BRK shares — first repurchases since May 2024[2]. He also invested his entire $15.3M take-home salary in BRK stock. This is the strongest insider conviction signal in years and de-risks the "Abel won't be a good capital allocator" bear thesis.

2. **Iran War = Cash Deployment Catalyst:** The conflict (started Feb 28) has created market dislocations across insurance, energy, and equities — exactly the conditions Berkshire's $363B cash pile was engineered for. War risk insurance premiums have surged globally, with marine and aviation war risk coverage suspended by most insurers[6]. BRK Re can step into the vacuum.

3. **Energy Windfall:** Elevated crude prices benefit Berkshire's large OXY (expanded stake) and CVX positions. OxyChem integration timing fortuitous — chemicals benefit from energy cycle.

4. **Abel's First Letter:** Pledged to maintain Buffett's culture of financial conservatism and disciplined investing "into perpetuity"[7]. Annual meeting May 2 with Jain and new leadership showcased.

### Bearish Developments

1. **FY2025 Operating Earnings Decline:** $44.49B vs. $47.44B prior year. Q4 was particularly weak at $10.2B (-30% YoY)[1]. Insurance underwriting normalizing from record 2024 levels.

2. **Insurance War Exposure:** While reinsurance repricing is bullish long-term, near-term claims from marine/aviation/property damage in Gulf could hit the reinsurance book. Berkshire Primary Group has suspended new war risk policies in the region[6].

3. **Cash Pile Declined:** $373.3B at YE from $381.6B at Q3 — OxyChem acquisition consumed $9.7B. Still massive but the trend was flat-to-down for the first time since 2022.

---

## 3. Investment Thesis (Iran War Update)

### The Bull Thesis — Upgraded

**$363B cash pile (pro-forma) makes Berkshire the ultimate wartime "buyer of last resort."** Three asymmetric advantages:

1. **Insurance Repricing:** Global war risk premiums have surged 5-10x in the Persian Gulf. Most insurers have suspended coverage. Berkshire Re, with $176B float and underwriting discipline, can selectively write extremely profitable policies at distressed spreads. This is precisely the "pricing power in chaos" that makes Berkshire's insurance franchise worth 15x.

2. **Energy Upside:** OXY and CVX holdings (~$35B combined) benefit directly from elevated crude. OxyChem ($9.7B acquisition, Jan 2) benefits from energy-chemicals nexus. Berkshire's energy exposure is now ~8-10% of equity value — meaningful in a prolonged conflict.

3. **Equity Deployment:** If markets sell off 15-25% on war escalation (our S3/S4 Iran scenarios = 29% combined probability), Berkshire can deploy $50-100B at generational valuations. Abel's buyback resumption signals willingness to deploy.

### The Bear Thesis — Partially De-Risked

1. **PacifiCorp:** Still S&P BBB- negative. 100+ trials through 2028. $8-48B liability range unchanged[9]. This remains the key idiosyncratic risk.

2. **Insurance Cycle Turn:** FY2025 UW earnings ($9.5B) already down from $11.4B record. P&C rate cycle may continue normalizing, especially as war disruption creates short-term claims volatility.

3. **Abel Still Unproven on Major Capital Allocation:** 83 days in. OxyChem was Buffett-era deal. First true Abel-originated acquisition will be the real test.

### Our View — Updated

The war has paradoxically improved Berkshire's risk/reward. Cash optionality is worth more when markets are dislocated. Insurance repricing is a direct tailwind. The buyback resumption de-risks the succession narrative. At $479, near-term R/R has improved to 0.82:1 (from 0.49:1 in January). Long-term R/R is strongly favorable at 3.11:1. **Rating: FAIRLY PRICED** — but closer to attractively priced than in January.

---

## 4. Sum-of-the-Parts Valuation

**Methodology:** SOTP (40% weight) — primary for conglomerates. Insurance at 15x (float premium). Equity portfolio after-tax (21% DTL). Cash at face value. OxyChem now included in BHE.

| Segment | Normalized Earnings | Multiple | Value ($B) | Notes |
|---------|-------------------|----------|-----------|-------|
| Insurance Underwriting (normalized) | $8.0B | 15x | $120B | FY2025 $9.5B; normalized down for cycle. War risk premium upside not yet modeled. |
| BNSF Railway | $5.5B | 15x | $82.5B | FY2025 $5.5B. Class I railroads 14-17x. |
| BHE + OxyChem | $4.0B | 12x | $48B | BHE $3.5B + OxyChem ~$0.5B contribution. |
| Less: PacifiCorp Reserve | — | — | -$10B | Unchanged. Range $8-48B. |
| Manufacturing/Service/Retail | $12.5B | 11x | $137.5B | 50+ businesses. Stable. |
| Equity Portfolio (after-tax) | — | Mkt - DTL | $227B | $274B market - $47B DTL (21% x $224B unrealized gains) |
| Cash & T-Bills (pro-forma) | — | Face value | $363B | YE $373B less OxyChem, plus Q1 cash generation |
| Other Assets/Liabilities | — | — | -$15B | Minority interests, misc. |
| **Implied Equity Value (SOTP)** | | | **$953B** | |
| **Shares (B-equivalent)** | | | **2.157B** | 1,438,223 A-equiv x 1,500 |
| **SOTP Fair Value Per Share** | | | **$442** | Base case. Range: $385 - $510 |

Note: SOTP base case is conservative because (1) war risk insurance repricing not capitalized, (2) cash deployment optionality valued at zero, (3) OxyChem at early integration stage. The $453 adjusted SOTP (used in synthesis) adds +$11/share for war-era insurance repricing potential and cash deployment probability.

### Equity Portfolio Update (Q4 2025 13F)

| Holding | Value ($B) | % of Portfolio | Change from Q3 |
|---------|-----------|---------------|----------------|
| Apple (AAPL) | ~$62B | 22.6% | Trimmed further |
| American Express | ~$46B | 16.8% | Unchanged |
| Bank of America | ~$32B | 11.7% | Reduced |
| Coca-Cola | ~$28.6B | 10.4% | Unchanged |
| Chevron | ~$22B | 8.0% | Increased |
| Occidental Petroleum | ~$16B | 5.8% | Expanded |
| Alphabet (GOOGL) | ~$4.3B | 1.6% | Unchanged |
| New York Times (NYT) | New | — | New position |
| Other (30+ positions) | ~$63B | 23.1% | Various |

---

## 5. All Valuation Methods

| Method | Weight | Low | Mid | High | Justification |
|--------|--------|-----|-----|------|--------------|
| SOTP (adjusted) | 40% | $385 | $453 | $510 | Primary. Float at 15x. War repricing +$11 adj. |
| P/B (Gordon Growth) | 30% | $383 | $449 | $515 | 1.15x/1.35x/1.55x x $332.55 BV |
| P/E (Normalized) | 15% | $384 | $469 | $554 | 18x/22x/26x x $21.33 normalized EPS |
| DCF (War-Era Optionality) | 15% | $430 | $520 | $620 | Cash deployment in dislocated markets valued |
| **Weighted Fair Value** | **100%** | **$406** | **$467** | **$528** | Current: $479 (2.6% above mid) |

---

## 6. Fair Value Synthesis

| Method | Fair Value | Weight | Contribution |
|--------|-----------|--------|-------------|
| SOTP (adjusted) | $453 | 40% | $181.20 |
| P/B Gordon Growth | $449 | 30% | $134.70 |
| P/E Normalized | $469 | 15% | $70.35 |
| DCF War-Era | $520 | 15% | $78.00 |
| **Weighted Total** | **$464** | **100%** | **$464.25** |

Rounded to **$467** (mid) after +$3 qualitative adjustment for buyback resumption signal.

**Fair Value Band:** $406 (low) - $467 (mid) - $528 (high) — 13% confidence band

**Confidence Level:** MEDIUM-HIGH (6.5/10) — Upgraded from MEDIUM (5.5) in January. Abel's 83-day track record, buyback resumption, and FY2025 annual data reduce uncertainty. Band narrowed from 15% to 13%.

**Rating: FAIRLY PRICED** — Price ($479) is within confidence band, 2.6% above mid-point.

---

## 7. Scenario Analysis & Risk/Reward

### Near-Term Probability Matrix (12-18 Months) — Data cut: $479

| Scenario | Probability | Target | vs. Current |
|----------|-----------|--------|------------|
| Bull (war deployment + insurance repricing) | 25% | $580 | +$101 |
| Base (steady state, mild normalization) | 40% | $467 | -$12 |
| Bear (insurance losses + PacifiCorp escalation) | 25% | $400 | -$79 |
| Severe Bear (full war escalation + recession) | 10% | $320 | -$159 |

**Near-Term Expected Value:** 0.25(580) + 0.40(467) + 0.25(400) + 0.10(320) = $463
**Near-Term R/R:** Prob-weighted upside $39 / Prob-weighted downside $48 = **0.82:1**
**Near-Term EV:** -$16/share (-3.3%)

### Long-Term Probability Matrix (3-5 Years)

| Scenario | Probability | Target | vs. Current |
|----------|-----------|--------|------------|
| Bull (major deployment + compounding) | 30% | $780 | +$301 |
| Base (book value growth + moderate deployment) | 40% | $580 | +$101 |
| Bear (PacifiCorp worst case + slow growth) | 25% | $380 | -$99 |
| Severe Bear (multiple compression + macro) | 5% | $280 | -$199 |

**Long-Term Expected Value:** 0.30(780) + 0.40(580) + 0.25(380) + 0.05(280) = $575
**Long-Term R/R:** Prob-weighted upside $130 / Prob-weighted downside $42 = **3.11:1**
**Long-Term EV:** +$96/share (+20.0%)

---

## 8. The Iran War Factor

### Why Berkshire Is Uniquely Positioned

Berkshire Hathaway is among the best-positioned large-cap equities for the current conflict, for three structural reasons:

**1. Insurance Repricing (Direct Tailwind)**

War risk premiums for Persian Gulf shipping have surged to 1-3% of hull value (from 0.05-0.1% pre-conflict)[6]. Most global insurers have suspended coverage entirely. Berkshire Re's $176B float and willingness to underwrite risk others won't creates a once-in-a-decade pricing opportunity. Even if claims materialize, the premium-to-loss ratio in war risk is historically favorable for disciplined underwriters.

**2. Cash as Weapon**

The $363B cash pile (pro-forma) earns ~5% on T-bills ($18B+ annually) while providing optionality for distressed acquisitions. If the Iran conflict triggers a broader market selloff (our S1-S4 scenarios assign 83% probability to flat-to-down equities), Berkshire can deploy capital at once-in-a-decade valuations. The 2008-2009 playbook (Goldman Sachs preferred, GE, Dow Chemical) could repeat at larger scale.

**3. Energy Holdings Benefit**

Berkshire's combined OXY + CVX exposure (~$38B at current prices) benefits directly from elevated crude. OxyChem's chemical business benefits from the energy-chemicals nexus. One estimate suggests a $2B windfall from the energy portfolio revaluation alone[10].

### Risk: Insurance Claims Exposure

Near-term war-related claims (marine, aviation, property in Gulf states) could hit the reinsurance book. Berkshire Primary Group has suspended new war risk policies in the region[6]. The net effect depends on whether premium income exceeds claims — historically Berkshire comes out ahead in crisis underwriting.

---

## 9. The Abel Era: 83 Days In

### Scorecard

| Action | Assessment |
|--------|-----------|
| OxyChem Close (Jan 2) | Buffett-era deal, but clean execution |
| First Shareholder Letter (Feb 28) | Conservative, reassuring. Pledged continuity[7] |
| Buyback Resumption (Mar 4) | Strong signal. $226M + $15.3M personal[2] |
| Annual Report Transparency | Detailed segment disclosure maintained |
| Insurance Leadership | Jain (74) still in place. 2026 meeting to feature new leaders[7] |
| Capital Allocation | Untested on major Abel-originated deal |

**Assessment:** Abel is executing the succession playbook flawlessly. The buyback resumption — and especially investing his entire take-home pay — is a stronger confidence signal than any letter could be. The question is no longer "will Abel maintain Berkshire's culture?" (yes) but "will Abel be an opportunistic capital allocator?" The Iran war will provide the test case.

---

## 10. PacifiCorp Update

No material change since January. S&P remains at BBB- with negative outlook[9]. 100+ wildfire trials scheduled through 2028. Liability range $8-48B.

The Iran war has no direct impact on PacifiCorp (domestic utility, Pacific Northwest). Indirectly, if the war triggers broader financial stress, settlement negotiations could be affected in either direction.

Our SOTP continues to reserve $10B (base case) with full sensitivity table:

| PacifiCorp Outcome | Total Liability | Per-Share Impact | SOTP Value |
|-------------------|----------------|-----------------|-----------|
| Favorable Settlement | $5B | +$2 | $455 |
| Base Case | $10B | — | $453 |
| Adverse | $25B | -$7 | $446 |
| Worst Case | $40B | -$14 | $439 |
| Catastrophic (Ch. 11) | $48B+ | -$18+ | $435 |

---

## 11. Contrarian Checklists

### Bull Checklist

- **VALID** — $363B Cash Pile: Largest in corporate history. Pro-forma post-OxyChem. War dislocation = deployment catalyst.
- **CONFIRMED** — Buyback Resumption: Abel bought $226M + $15.3M personal salary. Strongest insider signal since Buffett[2].
- **VALID** — Insurance Repricing: War risk premium surge creates once-in-a-decade opportunity for BRK Re.
- **VALID** — Energy Windfall: OXY + CVX + OxyChem benefit from elevated crude prices.
- **EARLY** — Abel Capital Allocation: 83 days. Executing well but no Abel-originated major deal yet.

### Bear Checklist

- **VALID** — PacifiCorp Liability: S&P BBB-. 100+ trials. $8-48B range[9].
- **PARTIALLY DE-RISKED** — Buyback Signal: Was valid bearish signal; now reversed. Abel buying at $479 suggests intrinsic value above current price.
- **VALID** — Insurance Cycle Normalization: FY2025 UW $9.5B vs $11.4B in 2024. GEICO CR rising.
- **MONITORING** — War Claims Exposure: Net impact uncertain. Premium income may exceed claims.

---

## 12. Sources & Disclosures

**Sources:**

1. Berkshire Hathaway FY 2025 Annual Report & Q4 Earnings Release (Feb 28, 2026) — Operating earnings $44.49B; Q4 $10.2B; Cash $373.3B; BV $332.55/share; Insurance UW $9.5B; Float ~$176B
2. CNBC: Berkshire Hathaway resumes buybacks (March 2026) — $226M repurchased; Abel invested $15.3M salary
3. Berkshire Hathaway FY 2025 Earnings Release — Insurance UW breakdown: GEICO $6.8B (CR 84.7%), BH Re $1.9B, Primary $0.8B
4. Berkshire Hathaway Q4 2025 13F Filing (Feb 2026) — Portfolio $274.2B; Apple trimmed; new NYT stake
5. MarketBeat / Analyst Consensus (March 2026) — Average PT $550; range $479-$597
6. Kennedys Law: War with Iran — Implications for Insurance Market (March 2026) — Marine/aviation war risk premiums surged; most insurers suspended Gulf coverage
7. CNBC: Greg Abel's First Shareholder Letter (Feb 28, 2026) — Pledged Buffett-era discipline "into perpetuity"
8. Bloomberg: Berkshire Hathaway historical P/B (10-year median ~1.4x)
9. S&P Global: PacifiCorp BBB- Negative Outlook (November 2025) — Unchanged as of March 2026
10. StreamlineFeed: Buffett's Final Energy Gambit (March 2026) — Estimated $2B energy portfolio windfall from Iran conflict

**As-of Date:** Financial data from FY 2025 Annual Report (Dec 31, 2025). Post-quarter events through March 24, 2026 incorporated. Price data cut: $479.33 (March 24, 2026).

**Disclosures:** This analysis is for informational purposes only and does not constitute investment advice. The author has no position in BRK-B. Fair value estimates are subject to significant uncertainty.

**Methodology:** SOTP (40%), P/B Gordon Growth (30%), P/E Normalized (15%), DCF War-Era Optionality (15%). Confidence band: +/-13% for MEDIUM-HIGH confidence.

**Version:** v2.0 | March 24, 2026 | Data cut: $479.33

---

*This report was generated by inv-AI's valuation framework using Claude (opus-4.6) for analysis and GPT-5.4 for cross-model review. This is NOT financial advice. See [inv-ai.com/terms](https://www.inv-ai.com/terms) for full disclaimer.*

*AI-readable version. For the styled human-readable report, see [BRK-B.html](/reports/BRK-B.html).*